Biomea Fusion Balance Sheet Health

Finanzielle Gesundheit Kriterienprüfungen 4/6

Biomea Fusion hat ein Gesamteigenkapital von $76.0M und eine Gesamtverschuldung von $0.0, was einen Verschuldungsgrad von 0% ergibt. Die Gesamtaktiva und Gesamtpassiva betragen $110.4M bzw. $34.4M.

Wichtige Informationen

Verhältnis von Schulden zu Eigenkapital

US$0

Verschuldung

Zinsdeckungsgrad	n/a
Bargeld	US$87.95m
Eigenkapital	US$75.97m
Gesamtverbindlichkeiten	US$34.45m
Gesamtvermögen	US$110.42m

Jüngste Berichte zur Finanzlage

Here's Why We're Not Too Worried About Biomea Fusion's (NASDAQ:BMEA) Cash Burn Situation

Mar 29

Recent updates

We're Keeping An Eye On Biomea Fusion's (NASDAQ:BMEA) Cash Burn Rate

Sep 30

We Think Biomea Fusion (NASDAQ:BMEA) Needs To Drive Business Growth Carefully

Jun 10

We Think Biomea Fusion (NASDAQ:BMEA) Can Afford To Drive Business Growth

Feb 22

Is Biomea Fusion (NASDAQ:BMEA) In A Good Position To Invest In Growth?

Nov 07

We Think Biomea Fusion (NASDAQ:BMEA) Needs To Drive Business Growth Carefully

Jul 12

Here's Why We're Not Too Worried About Biomea Fusion's (NASDAQ:BMEA) Cash Burn Situation

Mar 29

We're Hopeful That Biomea Fusion (NASDAQ:BMEA) Will Use Its Cash Wisely

Nov 03

Biomea Fusion GAAP EPS of -$0.59 beats by $0.01

Aug 01

We're Not Very Worried About Biomea Fusion's (NASDAQ:BMEA) Cash Burn Rate

Jul 20

Biomea Fusion (NASDAQ:BMEA) Is In A Good Position To Deliver On Growth Plans

Mar 16

Here's Why We're Not Too Worried About Biomea Fusion's (NASDAQ:BMEA) Cash Burn Situation

Nov 27

Biomea Fusion: Patience Warranted

Sep 23

Analyse der Finanzlage

Kurzfristige Verbindlichkeiten: BMEADie kurzfristigen Aktiva des Unternehmens ($93.6M) übersteigen seine kurzfristigen Passiva ($27.6M).

Langfristige Verbindlichkeiten: BMEADie kurzfristigen Vermögenswerte des Unternehmens ($93.6M) übersteigen seine langfristigen Verbindlichkeiten ($6.9M).

Geschichte und Analyse des Verhältnisses von Schulden zu Eigenkapital

Verschuldungsgrad: BMEA ist schuldenfrei.

Schulden abbauen: BMEA hatte vor 5 Jahren keine Schulden.

Bilanz

Liquiditätsreserve-Analyse

Bei Unternehmen, die in der Vergangenheit im Durchschnitt Verluste gemacht haben, wird geprüft, ob sie über einen Liquiditätsvorlauf von mindestens einem Jahr verfügen.

Stabile Start- und Landebahn für Bargeld: BMEA hat auf der Grundlage seines derzeitigen freier Cashflows weniger als ein Jahr Liquiditätsspielraum.

Vorhersage Cash Runway: BMEA hat weniger als ein Jahr Liquiditätsreserven, wenn der freie Cashflow weiterhin mit den historischen Raten von 48.5% pro Jahr abnimmt

Biomea Fusion Balance Sheet Health

Finanzielle Gesundheit Kriterienprüfungen 4/6

Wichtige Informationen

Jüngste Berichte zur Finanzlage

We're Keeping An Eye On Biomea Fusion's (NASDAQ:BMEA) Cash Burn Rate

We Think Biomea Fusion (NASDAQ:BMEA) Needs To Drive Business Growth Carefully

We Think Biomea Fusion (NASDAQ:BMEA) Can Afford To Drive Business Growth

Is Biomea Fusion (NASDAQ:BMEA) In A Good Position To Invest In Growth?

We Think Biomea Fusion (NASDAQ:BMEA) Needs To Drive Business Growth Carefully

Here's Why We're Not Too Worried About Biomea Fusion's (NASDAQ:BMEA) Cash Burn Situation

Recent updates

Biomea Fusion, Inc. Presents the New Analysis from the Escalation Portion of COVALENT-111 at the 1st Annual Asian Conference on Innovative Therapies for Diabetes Management

Biomea Fusion Presents Preclinical Data Showing Icovamenib (BMF-219) Enhanced Effectiveness of GLP-1-Based Therapies and Introduces BMF-650, a Next-Generation, Oral Small-Molecule GLP-1 Receptor Agonist Candidate

High number of new and inexperienced directors

Independent Director recently bought US$101k worth of stock

Biomea Announces Formation of Global Scientific Advisory Board with 22 World-Renowned Diabetes Experts

We're Keeping An Eye On Biomea Fusion's (NASDAQ:BMEA) Cash Burn Rate

Biomea Fusion, Inc. Announces FDA Lifts Clinical Hold on BMF-219 in Type 2 and Type 1 Diabetes Trials

New major risk - Financial position

High number of new and inexperienced directors

CFO & Principal Accounting Officer recently bought US$55k worth of stock

We Think Biomea Fusion (NASDAQ:BMEA) Needs To Drive Business Growth Carefully

Price target decreased by 17% to US$41.00

Biomea Fusion, Inc. Announces BMF-219 in Diabetes Placed on Clinical Hold

New major risk - Share price stability

Biomea Fusion, Inc. Announces Completion of Enrollment of First 3 Arms in Phase 2 Expansion Cohorts of COVALENT-111 Study for BMF-219 in Type 2 Diabetes

Price target increased by 10% to US$54.43

Biomea Fusion, Inc., Annual General Meeting, Jun 12, 2024

Biomea Fusion, Inc. Announces Initial Response Data from the First Two Type 1 Diabetes Patients Treated with Bmf-219 in the Ongoing Phase Ii Study (Covalent-112)

Price target decreased by 9.2% to US$49.38

Biomea Fusion, Inc. Presents Patient Cohorts in COVALENT-111 Displaying a Durable Placebo-Adjusted Mean Reduction of up to 1.4% in HbA1c While Off Therapy at Week-26, after BMF-219’s 28-Day Treatment Cycle, Supporting Improved Pancreatic Function

We Think Biomea Fusion (NASDAQ:BMEA) Can Afford To Drive Business Growth

Biomea Fusion Announces Dosing of First Type 1 Diabetes Patient in Phase Ii Study (Covalent-112) with BMF-219

New major risk - Revenue and earnings growth

Biomea Fusion, Inc. Presents Long-Term Follow-Up Data Showing Improved Glycemic Control After 22 Weeks Off Treatment in Ongoing Phase II Study (COvalent-111) of BMF-219 in Adults with Type 2 Diabetes in A Poster Presentation at the World Congress Insulin Resistance, Diabetes

Biomea Fusion, Inc. Announces Health Canada Clearance of Clinical Trial Application (CTA) for BMF-219 in Type 1 Diabetes

New minor risk - Share price stability

Biomea Fusion to Present New Data from Ongoing Phase II Study (COVALENT-111) of BMF-219 in Patients with Type 2 Diabetes at the World Congress Insulin Resistance, Diabetes & Cardiovascular Disease (WCIRDC)

Is Biomea Fusion (NASDAQ:BMEA) In A Good Position To Invest In Growth?

New major risk - Revenue and earnings growth

Biomea Fusion Announces Two Poster Presentations At Upcoming Ash Annual Meeting 2023

Biomea Fusion, Inc. Announces First Patient Dosed with Covalent FLT3 Inhibitor BMF-500 in Relapsed or Refractory Acute Leukemia in Phase I Clinical Trial (COVALENT-103)

Biomea Fusion Announces Fda and Health Canada Clearance of the Expansion Cohorts of the Ongoing Covvalent-111 Phase Ii Study

Biomea Fusion Announces Appointment of Juan Pablo Frías, M.D. as Chief Medical Officer

New major risk - Revenue and earnings growth

New major risk - Revenue and earnings growth

Biomea Fusion, Inc. Announces Preliminary Topline Data from Its Ongoing Phase I Clinical Trial, Covalent-101, Showcasing Initial Responses in Relapsed/Refractory Aml Patients with Menin-Dependent Mutations

We Think Biomea Fusion (NASDAQ:BMEA) Needs To Drive Business Growth Carefully

Price target increased by 17% to US$48.63

Biomea Fusion, Inc. Presents Positive Clinical Data from the Initial Cohorts of the Ongoing Phase II Study of BMF-219 in Patients with Type 2 Diabetes Mellitus at the American Diabetes Association 83rd Scientific Sessions

Biomea Fusion, Inc. Announces FDA Clearance of Investigational New Drug Application for Covalent FLT3 Inhibitor BMF-500 in Relapsed or Refractory Acute Leukemia

Here's Why We're Not Too Worried About Biomea Fusion's (NASDAQ:BMEA) Cash Burn Situation

Price target increased by 24% to US$27.50

Biomea Fusion Doses First Patient in Phase I/Ib Clinical Trial (COVALENT-102) of BMF-219 in KRAS Mutant Solid Tumors

Biomea Fusion, Inc. Announces Dosing of First Patient with Type 2 Diabetes in the United States in Ongoing Phase I/II (Covalent-111) Study of Bmf-219

Biomea Fusion, Inc. Announces FDA Clearance of Investigational New Drug (IND) Application for Covalent Menin Inhibitor BMF-219 in Type 2 Diabetes

Biomea Fusion, Inc. Presents at the 2022 ASH Annual Meeting Preclinical Data on BMF-500 Supporting its Potential as the Most Potent and Selective FLT3 Inhibitor to Date

High number of new and inexperienced directors

We're Hopeful That Biomea Fusion (NASDAQ:BMEA) Will Use Its Cash Wisely

Biomea Fusion, Inc. Announces Dosing of First Patient with Type 2 Diabetes and Completion of Phase I Healthy Volunteer Portion of Phase I/II (COVALENT-111) Study of BMF-219

Price target increased to US$23.60

Biomea Fusion, Inc. Announces First Patient Dosed with Chronic Lymphocytic Leukemia (Cll) in Covalent-101 Trial

FDA Clears Biomea's IND Application to Begin A Phase I/Ib Trial of BMF-219

Biomea Fusion Presents New Preclinical Data At the European Association for the Study of Diabetes (Easd) Annual Meeting Describing Bmf-219’S Potential as A Novel, Oral, Long-Acting Treatment for Type 2 Diabetes

Biomea Fusion GAAP EPS of -$0.59 beats by $0.01

We're Not Very Worried About Biomea Fusion's (NASDAQ:BMEA) Cash Burn Rate

Biomea Fusion, Inc.(NasdaqGS:BMEA) dropped from Russell 2000 Growth Index

Biomea Fusion, Inc. Appoints Elizabeth Faust as Class I Director

Biomea Fusion, Inc. Announces First Patient Dosed in Multiple Myeloma Cohort of COVALENT-101 Trial

Biomea Fusion to Present New Preclinical Data on BMF-219 in Two Diabetic Animal Models At Ada 2022

Price target decreased to US$19.50

Biomea Fusion, Inc. Announces IND Candidate Selection: BMF-500, a Potential Best-in-Class Oral Covalent Inhibitor of FLT3

Biomea Fusion, Inc., Annual General Meeting, Jun 22, 2022

Price target decreased to US$21.00

High number of new and inexperienced directors

Biomea Fusion Reports Preclinical Data on BMF-219 and Trial in Progress Presentations at AACR 2022 Annual Meeting

High number of new and inexperienced directors

Biomea Fusion (NASDAQ:BMEA) Is In A Good Position To Deliver On Growth Plans

Biomea Plans to Initiate Enrollment of Patients with MM and Diffuse Large B-Cell Lymphoma (DLBCL) in the Ongoing Phase I Clinical Trial of BMF-219 in the First Half of 2022

Biomea Fusion, Inc. Appoints Steve Morris, M.D. as Chief Medical Officer